IL17A and acute kidney injury: Bai et al. found that IL-17A pretreatment enhances the efficacy of MSCs on mice with ischemia-reperfusion acute kidney injury (IRI-AKI) by increasing the Treg percentages through the COX-2/PGE2 pathway [25].